News

InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update
INF904 Phase 2a data in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected by the end of September to early November 2025Phase 1/2 data announced by Staidson ...
InflaRx N.V.: InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update
INF904 Phase 2a data in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected by the end of September to early November 2025Phase 1/2 data announced by Staidson BioPharmaceuti ...